WARRINGTON, Pa., Oct. 30, 2007 (PRIME NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announced today that they will be hosting a conference call on Tuesday, November 6, 2007 at 10:00 AM EST. Management will discuss financial results for the third quarter and provide an overall business update.
Participants are encouraged to access this audio webcast through a live broadcast on the Company's website at www.discoverylabs.com. The webcast is also accessible on the Internet http://investor.shareholder.com/media/eventdetail.cfm?mediaid=28181&c=DSCO&mediakey=ABF4BD2E2D560BD815F42981FF75CF04&e=0. It is recommended that participants log onto one of these sites at least 15 minutes prior to the call. The Internet broadcast will be available for up to 30 days after the call at both website addresses.
The call in number is 866-332-5218. The international call in number is 706-679-3237. The replay number to hear the conference call is 800-642-1687 or 706-645-9291. The passcode is 21886657.
About Discovery Labs
Discovery Laboratories, Inc. is a biotechnology company developing Surfactant Replacement Therapies (SRT) for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' technology produces a precision-engineered surfactant that is designed to closely mimic the essential properties of natural human lung surfactant. Discovery Labs believes that its proprietary SRT pipeline has the potential to advance respiratory medicine and address a variety of respiratory diseases affecting neonatal, pediatric and adult patients.
Discovery Labs' lead product candidate, Surfaxin(r), is the subject of an Approvable Letter from the FDA for the prevention of Respiratory Distress Syndrome in premature infants. Surfaxin is also being developed for other neonatal and pediatric indications. Aerosurf(tm), Discovery Labs' aerosolized SRT, is being developed to potentially obviate the need for intubation and conventional mechanical ventilation and holds the promise to significantly expand the use of surfactants in respiratory medicine. For more information, please visit our website at www.Discoverylabs.com.